Enara Bio's purpose is to shine a light on unconventional T cell targets to develop cancer immunotherapies designed to provide lasting benefit for broad patient populations. Our proprietary EDAPT platform enables us to discover and validate novel and differentiated cancer-specific targets from the genomic dark matter, which we call Dark Antigens. We are advancing a pipeline of bispecific T-cell engagers against novel Dark Antigens and other underexploited targets for the treatment of patients with solid tumours.
Enara Bio was founded in 2016 and has been well funded to invest in the build out and growth of our R&D efforts and our fantastic team. The company is based in Oxford, UK.
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.